Here’s whether Royalty Pharma plc Class A Ordinary Shares (RPRX) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.64% over 10 days); strong 1-year return of +65.5%; 3-month momentum positive (+21.9%); rising volume confirms the move (1.25x 30d avg). Currently 0.4% off its 52-week high. Score: +7/7.
RPRX is in a confirmed uptrend, trading above both its 50-day ($50.74) and 200-day ($42.52) moving averages. An RSI of 66.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +65.5% compares to +24.4% for SPY (beat the market by 41.2%).
$10,000 invested 1 year ago→ $16,554 today
vs. S&P 500 (SPY) — same period beat market by 41.2%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($42.52)
✓Above 50-day MA ($50.74)
✓RSI(14) neutral zone (30–70) — currently 66.1
✓Positive return (+65.5%)
✓Within 10% of period high (−0.4%)
Period Range $55.87
$33.37$56.07
RSI (14) 66.1
0 · OversoldOverbought · 100
Key Metrics
Price$55.87
Period Return+65.5%
Period High$56.07
Period Low$33.37
Drawdown−0.4%
MA-50$50.74
MA-200$42.52
RSI (14)66.1
Avg Volume (30d)4.2M
vs. SPYbeat by 41.2%
Return Rank#287 of 1245
Trend Signals
Price is above the 200-day moving average ($42.52)